13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001615982
Total reported value
$3.3B
$3.3B
38 檔
29.8%
In Q1 2024, Venrock Adviser, LLC's U.S. equity holdings reached a combined market value of $3.3B, distributed across 38 disclosed stock positions.
During Q1 2024, Venrock Adviser, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including APGE, FDMT, OCUL) accounted for 29.8% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 26.85% | +7.50% | — | |
| 2 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 6.67% | — | +28.50% | |
| 3 | OCUL | Ocular Therapeutix Inc | Stock-Other | 5.52% | -0.19% | +64.13% | |
| 4 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.92% | +1.10% | -8.47% | |
| 5 | ✓ | Merus N V | Stock-Other | 3.83% | — | -16.66% | |
| 6 | PHVS | Pharvaris N.V. | Stock-Other | 3.73% | — | — | |
| 7 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.53% | -4.86% | EXIT | |
| 8 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.37% | -1.72% | +36.26% | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.23% | -1.02% | +0.00% | |
| 10 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.99% | -0.21% | +125.76% | |
| 11 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.94% | -0.01% | — | |
| 12 | APLT | Applied Therapeutics Inc | Stock-Other | 2.94% | — | +45.20% | |
| 13 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.87% | -0.62% | +80.97% | |
| 14 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.42% | — | +11.87% | |
| 15 | ✓ | Mersana Therapeutics Inc | Stock-Other | 2.41% | — | — | |
| 16 | ✓ | Engene Holdings Inc | Stock-Other | 2.07% | -1.21% | EXIT | |
| 17 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.05% | — | +99.68% | |
| 18 | ✓ | Hillevax Inc | Stock-Other | 1.64% | — | — | |
| 19 | COGT | Cogent Biosciences Inc | Stock-Other | 1.64% | -0.94% | +9.50% | |
| 20 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.58% | — | — | |
| 21 | CABA | Cabaletta Bio Inc | Stock-Other | 1.27% | — | -39.00% | |
| 22 | ARVN | Arvinas Inc | Stock-Other | 1.23% | — | — | |
| 23 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.23% | — | -13.57% | |
| 24 | AQST | Aquestive Therapeutics Inc | Stock-Other | 1.13% | — | — | |
| 25 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.06% | — | -24.17% | |
| 26 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 1.05% | — | — | |
| 27 | CELC | Celcuity Inc | Stock-Other | 1.00% | — | -48.56% | |
| 28 | ABVX | Abivax Sa-adr | Stock-Other | 0.92% | — | +34.77% | |
| 29 | ✓ | Immatics NV | Stock-Other | 0.87% | — | — | |
| 30 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 0.76% | — | +0.02% | |
| 31 | CGON | Cg Oncology Inc | Stock-Other | 0.73% | — | — | |
| 32 | IPSC | Century Therapeutics Inc | Stock-Other | 0.68% | -0.08% | — | |
| 33 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.56% | — | +0.01% | |
| 34 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.39% | — | — | |
| 35 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 36 | ✓ | Acelyrin Inc | Stock-Other | 0.30% | — | — | |
| 37 | EYPT | Eyepoint Inc | Stock-Other | 0.25% | — | — | |
| 38 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.04% | — | — |
According to official SEC Form 13F filings, Venrock Adviser, LLC reported a total U.S. public equity portfolio value of $3.3B across 38 disclosed positions in Q1 2024.
During Q1 2024, Venrock Adviser, LLC's top holdings by market value included APGE (26.9%)、FDMT (6.7%)、OCUL (5.5%). The largest single position, APGE, represented 26.9% of total portfolio value.
In Q1 2024, Venrock Adviser, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.